Drug therapy as an alternative to surgical intervention is becoming increasingly common. In the past five years, new anti-glaucoma agents have becoming increasingly effective. This edition will include new information on off-label prescribing and cap colors where they are mandated by the FDA (pink/white for steroid drops, grey for topical NSAIDS, etc.);There are now several new pharmaceutical agents being used to treat retinal diseases such as age-related macular degeneration (Macugen, Lucentis, Visudyne), while other drugs formerly prescribed have now been shown to be less effective. Intraocular infections are primarily treated with intravitreal medications. Additionally, the anti-allergy and dry eye markets continue to grow, with a new formulation of Allergan's Acular 0.5% (ketorolac tromethamine) and Elestat ophthalmic solution, its new antihistamine-mast cell stabilizer.
Authors and Affiliations
Boston, USA
Douglas J. Rhee
Massachusetts Eye & Ear Infirmary, Harvard Medical School, Boston, USA
Kathryn A. Colby,
Lucia Sobrin
Wills Eye Hospital, Philadelphia, USA
Christopher J. Rapuano
About the authors
Douglas J. Rhee, MD
Assistant Professor
Harvard Medical School
Associate Chief, Practice Development
Massachusetts Eye & Ear Infirmary
Boston, Massachusetts USA
Katheryn A. Colby, MD, PhD
Assistant Professor
Harvard Medical School
Cornea Service
Massachusetts Eye & Ear Infirmary
Boston, Massachusetts USA
Christopher J. Rapuano, MD
Professor
Jefferson Medical College
Director, Cornea Service
Wills Eye Hospital
Philadelphia, Pennsylvania USA
Lucia Sobrin, MD, MPH
Assistant Professor
Harvard Medical School
Massachusetts Eye & Ear Infirmary
Boston, Massachusetts USA
Bibliographic Information
Book Title: Ophthalmologic Drug Guide
Authors: Douglas J. Rhee, Kathryn A. Colby, Lucia Sobrin, Christopher J. Rapuano
